For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-driven disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-drive disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
Transcript
How does the immune pathway play a role in atopic dermatitis?
Atopic dermatitis is an evolving field and for many years there was a debate whether it is primarily a barrier disease or primarily an immune-driven disease. There was not a clear-cut answer because the only way to prove it is actually to target specifics to the immune system and to show that you reversed the barrier. And that was not possible really until dupilumab.
There were some hints toward it. There were some immune-based treatments cyclosporine and methotrexate and itolizumab. And they all work, However, they do have some effects on keratinocyte and also they are very broad, so it is not really proving the immune hypothesis. To prove the immune hypthesis you need to take a single cytokine or 2 cytokines, like in this case, target them and then show that you reversed the barrier, and that's proving the immune hypothesis.
And that's exactly what happened here. Because with dupilumab we showed that not only the clinical disease activity was reversed, but by suppressing the cytokines, you also reversed major features of the barrier, such as the thickness, the epidermal hyperplasia. The S100 proteins are increased. You show the trend to improve filaggrin and loricrin.
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen